doi: 10.2147/TCRM.S325916 Summary Keywords diabetic kidney disease, Mexico, chronic kidney disease, diabetes, iSLGT2, GLP-1 Citation Palomo-Pin S, Aguilar-Alonso JA, Chvez-Iiguez JS, Hernndez-Arellanes FE, Mariano-Murga JA, Flores-Rodrguez JC, Prez-Lpez MJ, Pazos-Prez F, Trevio-Becerra A, Guillen-Graf AE, Ramos-Gordillo JM, Trinidad-Ramos P and Antonio-Villa NE (2024) Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists
Wegovy is provided in a standardized dosage and must adhere to strict FDA regulations, ensuring that patients receive a reliable product
PMC 4894846
Jump to: Understanding GLP-1 medications | Commercial GLP-1 patches | The science of transdermal delivery | GLP-1 injections: evidence and efficacy | Safety comparison | UK considerations | Frequently asked questions | Take home message There is no clinical evidence that GLP-1 patches work for weight loss
Arpasova and L